16 September 2022 ORYZON to present preliminary blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder
29 September - 1 October 2022 XIX Congress of the Spanish Society of Psychogeriatrics Valladolid Spain
19 July 2022 ORYZON enters cooperative research and development agreement (CRADA) with U.S. National Cancer Institute to develop iadademstat in different cancers